Objective: To define a predictor of prostate cancer in BPH patients with an intermediate PSA (4.1-10 ng/ml) and a negative initial sextant biopsy. Patients and Methods During 1999, 193 BPH patients with an intermediate PSA (4.1-10 ng/ml) underwent TRUS and sextant biopsy. The patients whose initial biopsies were negative for prostate cancer were re-evaluated by serum PSA every 6 months. A total of 76 patients were subjected to an extended 11-core biopsy in view of: (1) PSA velocity ≥ 1 ng/ml/year, (2) a PSA rise to > 10 ng/ml and (3) suspicious biopsy findings (atypical adenomatous hyperplasia or high-grade prostatic intraepithelial neoplasia). Overall, 160 patients were subjected either to TURP (n=127) or open prostatectomy (n=33).Re...
The association between PSA density, prostate cancer (PCa) and BPH is well established. The aim of t...
OBJECTIVES: The risks of identifying prostate cancer (PCa) in patients with serum total PSA (tPSA) b...
In the Netherlands, prostate cancer is the most commonly diagnosed malignancy and the second leading...
BackgroundThis study aimed to analyze the pathological characteristics and predictive factors of pro...
Background: The aim of our study was to identify the optimal predictor of prostate cancer among seve...
© 2020, University of Kragujevac, Faculty of Science. All rights reserved. Serum prostate-specific a...
Objective: In this study, we aimed to investigate sufficiency of 6 core prostate biopsy in patients ...
Purpose: We compare the ability of total prostate specific antigen (PSA), percent free PSA, PSA dens...
AbstractBackgroundThe aim of our study was to identify the optimal predictor of prostate cancer amon...
In the early years of screening for prostate cancer with serum PSA, absolute cutoffs were typically ...
Background: The optimal extent of the prostate biopsy remains controversial. There is a need to avoi...
Background: The standard of care in patients with suspected prostate cancer (PCa) is systematic pros...
BACKGROUND: The present study aimed to evaluate the indications for a second prostate biopsy in pati...
OBJECTIVE: The aim of the study was to investigate the influence of the prostate volume and PSA dens...
he association between PSA density, prostate cancer (PCa) and BPH is well established. The aim of th...
The association between PSA density, prostate cancer (PCa) and BPH is well established. The aim of t...
OBJECTIVES: The risks of identifying prostate cancer (PCa) in patients with serum total PSA (tPSA) b...
In the Netherlands, prostate cancer is the most commonly diagnosed malignancy and the second leading...
BackgroundThis study aimed to analyze the pathological characteristics and predictive factors of pro...
Background: The aim of our study was to identify the optimal predictor of prostate cancer among seve...
© 2020, University of Kragujevac, Faculty of Science. All rights reserved. Serum prostate-specific a...
Objective: In this study, we aimed to investigate sufficiency of 6 core prostate biopsy in patients ...
Purpose: We compare the ability of total prostate specific antigen (PSA), percent free PSA, PSA dens...
AbstractBackgroundThe aim of our study was to identify the optimal predictor of prostate cancer amon...
In the early years of screening for prostate cancer with serum PSA, absolute cutoffs were typically ...
Background: The optimal extent of the prostate biopsy remains controversial. There is a need to avoi...
Background: The standard of care in patients with suspected prostate cancer (PCa) is systematic pros...
BACKGROUND: The present study aimed to evaluate the indications for a second prostate biopsy in pati...
OBJECTIVE: The aim of the study was to investigate the influence of the prostate volume and PSA dens...
he association between PSA density, prostate cancer (PCa) and BPH is well established. The aim of th...
The association between PSA density, prostate cancer (PCa) and BPH is well established. The aim of t...
OBJECTIVES: The risks of identifying prostate cancer (PCa) in patients with serum total PSA (tPSA) b...
In the Netherlands, prostate cancer is the most commonly diagnosed malignancy and the second leading...